Laura Rodríguez-Noda
A5041727288- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Pneumocystis jirovecii pneumonia detection and treatment
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Streptococcal Infections and Treatments
- Intramuscular injections and effects
- Viral gastroenteritis research and epidemiology
- vaccines and immunoinformatics approaches
- Heparin-Induced Thrombocytopenia and Thrombosis
- Influenza Virus Research Studies
- Carbohydrate Chemistry and Synthesis
- Digital Imaging for Blood Diseases
- Animal Virus Infections Studies
- Virology and Viral Diseases
- Dermatological and COVID-19 studies
- Long-Term Effects of COVID-19
- Inflammasome and immune disorders
- Glycosylation and Glycoproteins Research
- Cell Image Analysis Techniques
- Viral Infections and Immunology Research
- Bacillus and Francisella bacterial research
- Occupational Health and Safety in Workplaces
Finlay Institute
2017-2024
ORCID
2022
University of Havana
2015
The zwitterionic Streptococcus pneumoniae serotype 1 polysaccharide (Sp1) is an important anchor point for our immune system to act against streptococcal infections. Antibodies can recognize Sp1 saccharides, and it has been postulated that elicit a T-cell-dependent reaction as be presented by MHC-II molecules. To unravel the molecular mode of action this unique we here describe chemical synthesis set fragments, ranging from 3 12 monosaccharides in length. We outline synthetic approach...
As a first step towards vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A in clinical trial.
The efficacy of protein and carbohydrate antigens as vaccines can be improved via particulate delivery strategies. Here, used in formulations against Neisseria menigitidis were displayed on vivo assembled polyester beads using a combined bioengineering conjugation approach. An endotoxin-free mutant Escherichia coli was engineered to produce translational fusions (Neisseria adhesin A (NadA) factor H binding (fHbp) derived from serogroup B) the polyhydroxybutyrate synthase (PhaC), order...
To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o) combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines.A phase I/II open-label, adaptive, and multicenter trial evaluated the safety immunogenicity of doses FINLAY-FR-2 (subsequently called SOBERANA 02) third dose FINLAY-FR-1A Plus) 350 y/o Havana Cuba. Primary outcomes were (phase I) safety/immunogenicity II) measured by anti-RBD immunoglobulin (Ig)G enzyme-linked immunoassay (ELISA), molecular...
Streptococcus pneumoniae is a human pathogen responsible for the majority of childhood pneumonia and media otitis cases worldwide. The diversity its capsular polysaccharides (CPS) results in more than 91 serotypes which at least 23 are virulent. Various CPS conjugated to immunogenic carrier proteins currently licensed provide protection against infection caused by respective but not new emerging virulent serotypes. In this study, we considered conserved protein antigen PsaA, pneumococcal...
Streptococcus pneumoniae can cause life-threatening infections mostly in infants, children, and elderly people. Capsular polysaccharide conjugate vaccines provide serotype-dependent protection against S. but fail to protect new emerging serotypes. To overcome these limitations, pneumolysin (Ply), a serotype-independent conserved protein was selected. As such subunit lack immunogenicity, we engineered Ply be attached self-assembled polyester beads order boost immunogenicity. display at the...
Background: A new vaccine candidate against pneumococcus is being developed in Cuba, and it a priority of the national health system. There limited information on nasopharyngeal colonization burden, though essential for monitoring impact vaccine. The study aims to estimate prevalence children 2–18 months age identify circulating serotypes, antimicrobial resistance its association with selected risk factors. Methods: cross-sectional was conducted between October December 2013 Cienfuegos...
Abstract We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during phase I clinical trial with 30 COVID-19 convalescents, test its capacity for boosting natural immunity. This short report shows: a) an excellent safety profile one month after vaccination all participants, similar that previously found naïve individuals; b) induces >20 fold increase in antibody week and remarkably 4-fold higher virus neutralization compared median obtained Cuban...
(1) Background: In children, SARS-CoV-2 infection is mostly accompanied by mild COVID-19 symptoms. However, multisystem inflammatory syndrome (MIS-C) and long-term sequelae are often severe complications. Therefore, the protection of pediatric population against with effective vaccines particularly important. Here, we compare humoral cellular immune responses elicited in children (n = 15, aged 5–11 years) vaccinated RBD-based SOBERANA® 02 Plus combined a heterologous scheme those from 10,...
Abstract Background We report results of immunogenicity, safety and reactogenicity SOBERANA 02 in a two-dose or three-dose heterologous scheme adults phase IIb clinical trial. Method This trial was designed as parallel, multicentre, adaptive, double blind, randomized placebo-controlled. Subjects (N=810) aged 19-80 years were to receive two doses the recombinant SARS CoV-2 receptor binding domain (RBD) conjugated tetanus toxoid (SOBERANA 02) third dose dimeric RBD Plus) 28 days apart;...
Abstract Background SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid. Plus antigen dimeric-RBD. Here we report safety, reactogenicity and immunogenicity from phase I IIa clinical trials using two-doses (homologous protocol) three-doses (homologous) or heterologous (with Plus) protocols. Method We performed an open-label, monocentric, sequential adaptive for evaluating exploring of in two formulations (15 25 μg) 40...
Abstract Background The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is target for many COVID-19 vaccines. Here we report results phase 1 clinical trial two vaccine candidates based on recombinant dimeric RBD (d-RBD). Methods We performed a randomized, double-blind, I in National Centre Toxicology Havana. Sixty Cuban volunteers aged 19-59 years were randomized into three groups (20 subjects each): 1) FINLAY-FR-1 (50 mcg d-RBD plus outer membrane vesicles from N. meningitidis...
Abstract Objectives To evaluate heterologous vaccination scheme in children 3-18 y/o combining two SARS-CoV-2 r-RBD protein vaccines. Methods A phase I/II open-label, adaptive and multicenter trial evaluated the safety immunogenicity of doses SOBERANA02 a third dose SOBERANA Plus 350 Havana Cuba. Primary outcomes were (in I) safety/immunogenicity II) measured by anti-RBD IgG ELISA, molecular live-virus neutralization titers specific T-cells response. comparison with adult‘s prediction...
Abstract Streptococcus pneumoniae is a bacterial pathogen causing diseases as severe pneumonia, sepsis and meningitis. Most commercial pneumococcal conjugate vaccines contain the 7F serotype, which epidemiologically relevant highly invasive. This serotype contains an O ‐acetyl group at internal L‐rhamnose of its polysaccharide repeating unit. Herein we report on role moiety in both antigen recognition induction protective antibody response against 7F. Fully partially de‐ ‐acetylated...
(1) Background: SARS-CoV-2 infection is mostly accompanied by mild COVID-19 symptoms in children. However, the multisystem inflammatory syndrome (MIS-C) and long-term sequelae are often severe complications. Therefore, protection of pediatric population against with effective vaccines particularly important. Here we compare humoral cellular immune responses elicited children (n=15) aged 5-11 years vaccinated RBD-based combined a heterologous scheme SOBERANA® 02 Plus those from (n=10) 4-11...
Introduction: As a part of repeated dose toxicity and local tolerance study the anti-Severe acute respiratory syndrome-Coronavirus-2 vaccine candidate FINLAY-FR-02, morphometric histopathological analysis was carried out to obtain more detailed understanding its effects on organs within immune system.Materials Methods: Sprague Dawley rats were divided into three groups: those vaccinated with doses (37.5 μg receptor binding domain), placebo group, controls.Tissue samples spleen, deep inguinal...